Brief: Epigenomics says incurred loss of more than half of nominal share capital of co
07/08/2017 19:15
Aug 7 (Reuters) - Epigenomics Ag ECXn.DE :
* EXECUTIVE BOARD NOTIFIES THAT A CUMULATIVE LOSS OF MORE
THAN HALF OF NOMINAL SHARE CAPITAL OF COMPANY HAS BEEN INCURRED
* LOSS OF MORE THAN HALF OF NOMINAL SHARE CAPITAL MAINLY
ATTRIBUTABLE TO BUDGETED LOSSES FROM REGULAR BUSINESS OPERATIONS
* REVIEWING DIFFERENT MEASURES TO IMPROVE COMPANY'S EQUITY
AND LIQUIDITY
Source text for Eikon: ID:nEQ5lGGGYa
Further company coverage: ECXn.DE
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns